Intracellular (ITCI) shares of the midcap Biotech are coiling up in a bull flag after a recent retracement to the rising 55 day MA near 82 held nicely and now prices closed strongly back inside monthly value on Monday higher by +2.5%. ITCI can see a swift move back up to the value high near 89 while a stronger move into early 2025 can see a 100 print. ITCI recently positive topline results in Phase 3 Trial Evaluating CAPLYTA for the prevention of relapse in patients with schizophrenia. ITCI still has nearly 1000 December $85 short puts in OI expiring this week.